Part of the post hoc analysis should include the trial design strategy.  BETonMACE was under-powered, and virtually everyone said so.   Therefore, use your head and make sure BETonMACE 2 is at least adequately powered, or if anything over-powered.  That way we actually INCREASE our chances of getting halted for overwhelming efficacy, thereby saving time and money.  Funny how that works.  The CEO and CFO need to wrap their heads around that.  We need a very large "N"

Go big, or stay home...it speaks to credibility